摘要
目的观察小剂量（10mg）来氟米特联合阿德福韦酯治疗合并慢性乙肝的IgA肾炎的临床疗效和安全性。方法22例伴乙肝的IgA肾炎和24例不伴乙肝的IgA肾炎分成两组，分别给予小剂量和全剂量（20mg）的来氟米特进行为期6个月的临床观察。结果两组蛋白尿均明显减轻（P〈0．01）），两组总有效率差异无统计学意义（P〉0．05）；血清白蛋白均明显提高（P〈0．01）；血脂紊乱改善且两组均没有严重的不良反应。结论小剂量的来氟米特治疗伴乙肝的IgA肾炎疗效肯定，无严重的不良反应。
Objective To investigate the effects and safety of low doses of leflunomide （10 mg/d） combined with the adefovir dipivoxil in the treatment of patients with IgA nephropathy and hepatitis B virus. Methods Twenty -two patients with IgA nephropathy and hepatitis B virus were treated with low doses of leflunomide combined with the adefovir dipivoxil. Another 24 cases of patients with IgA nephropathy no hepatitis B virus were treated with normal doses of leflunomide （20 mg/d） combined with the adefovir dipivoxil. Their therapeutic effects and safety were recorded and analysed through six months clinical observations respectively. Results Urinary protein of two group patients were both decreased obviously （P 〈 0. 01 ） ）. Serum albumin of two group patients were both obviously improved （P 〈 0.01 ）. The total effectiveness of the two groups were not statistically significant （P 〉 0. 05 ）. Only mild tolerable adverse effects were observed. Conclusions Low doses of leflunomide combined with adefovir dipivoxil therapy can be one of the safe and effective choices for treatment of patients with IgA nephropathy and hepatitis B virus.
出处
《中国实用医刊》
2011年第24期51-53,共3页
Chinese Journal of Practical Medicine
关键词
IGA肾炎
乙肝
来氟米特
阿德福韦酯
IgA Nephropathy
Hepatitis B virus
Leflunomide
Adefovir dipivoxil
